Literature DB >> 22410353

Treatment of multidrug-resistant tuberculosis in a high-prevalence region through a binational consortium.

R Laniado-Laborín1, J Estrada-Guzman, H Perez, F Batiz-Armenta, J M Alcantar-Schramm.   

Abstract

We describe the outcome of treatment of multidrug-resistant tuberculosis (MDR-TB) in Baja California, Mexico, by a United States-Mexico consortium. From June 2006 to December 2010, 42 patients started treatment. Strains were resistant to 4.15 ± 1.3 drugs; all patients achieved culture conversion on treatment after an average of 3.4 ± 1.6 months. A total of 19 patients (47.5%) were discharged as cured, 3 died (7.5%) and 1 defaulted (2.5%). MDR-TB cases can be cured under a well-organized out-patient program; in this consortium, the US partner introduced program elements that were gradually integrated into the Mexican state TB program.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410353     DOI: 10.5588/ijtld.11.0544

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  3 in total

1.  Multidrug-resistant tuberculosis among patients in Baja California, Mexico, and Hispanic patients in California.

Authors:  Ietza Bojorquez; Richard F W Barnes; Jennifer Flood; Hugo López-Gatell; Richard S Garfein; Claudia E Bäcker; Celia Alpuche; Joseph M Vinetz; Antonino Catanzaro; Midori Kato-Maeda; Timothy C Rodwell
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308

2.  Social, economic, and psychological impacts of MDR-TB treatment in Tijuana, Mexico: a patient's perspective.

Authors:  M D Morris; L Quezada; P Bhat; K Moser; J Smith; H Perez; R Laniado-Laborin; J Estrada-Guzman; T C Rodwell
Journal:  Int J Tuberc Lung Dis       Date:  2013-07       Impact factor: 2.373

3.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.